Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Pasi Antero Janne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Pasi Janne and Cloud Paweletz.
Connection Strength

1.162
  1. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd. Cancer Res. 2021 Sep 21.
    View in: PubMed
    Score: 0.246
  2. ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. Mol Cancer Ther. 2021 04; 20(4):641-654.
    View in: PubMed
    Score: 0.236
  3. Use of ExVivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 05 15; 26(10):2393-2403.
    View in: PubMed
    Score: 0.220
  4. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5963-5976.
    View in: PubMed
    Score: 0.198
  5. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug; 11(8):1952-1969.
    View in: PubMed
    Score: 0.059
  6. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
    View in: PubMed
    Score: 0.059
  7. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625.
    View in: PubMed
    Score: 0.055
  8. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 09 15; 24(18):4437-4443.
    View in: PubMed
    Score: 0.048
  9. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14.
    View in: PubMed
    Score: 0.040
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.